1.
Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung
neuroendocrine. Thorac Surg Clin. 24: 257-266; 2014.
2.
Parsons HM, Harlan LC, Stevens JL, Ullmann CD. Treatment of small cell lung
cancer in academic and community settings: factors associated with receiving
standard therapy and survival. Cancer J. 20: 97-104; 2014.
3.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ,
Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames
DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung
Cancer. N Engl J Med. 379: 2220-2229; 2018.
4.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G,
Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame
F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J,
Byrne N, Shire N, Jiang H, Goldman JW. Durvalumab plus platinum-etoposide
versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung
cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet.
394: 1929-1939; 2019.
5.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X,
Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang
D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM,
Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic
I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T,
Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I,
76
Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y,
Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M,
Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E,
Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J,
Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V,
Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron
M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner
R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic
profiles of small cell lung cancer. Nature. 524: 47-53; 2015.
6.
Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R,
Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC,
Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE,
Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC,
Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG,
Hughes M. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J
Natl Compr Canc Netw. 16: 1171-1182; 2018.
7.
Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, Tolia M, Tsapakidis K,
Galanopoulos M, Liontos M, Kyrgias G. Advanced small cell lung cancer (SCLC):
new challenges and new expectations. Ann Transl Med. 6: 145; 2018.
8.
Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S,
Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He
L, Komarnitsky P, Calles A. A Phase I Dose-Escalation Study of Veliparib
Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small
Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res. 25: 496-505; 2019.
9.
Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL, 3rd, Srkalovic G,
77
Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS. Randomized Phase II
Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for
Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin
Oncol. 37: 222-229; 2019.
10.
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A,
Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J,
Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba, II, Chen A, Fleisher M,
Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase
II Study of Temozolomide in Combination With Either Veliparib or Placebo in
Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin
Oncol. 36: 2386-2394; 2018.
11.
Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A,
Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N,
Dowlati A, Massion PP, Rudin CM, Poirier JT. Chemosensitive Relapse in Small
Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31: 286299; 2017.
12.
Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 394:
793-804; 2019.
13.
Polakis P. Antibody Drug Conjugates for Cancer Therapy. Pharmacol Rev. 68: 319; 2016.
14.
Tsuchikama KAn Z. Antibody-drug conjugates: recent advances in conjugation and
linker chemistries. Protein Cell. 9: 33-46; 2018.
15.
Chalouni CDoll S. Fate of Antibody-Drug Conjugates in Cancer Cells. J Exp Clin
Cancer Res. 37: 20; 2018.
16.
Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E,
78
Bogalhas M, Wang L, Dong L, Setiady Y, Maloney EK, Ab O, Zhang X, Pinkas J,
Keating TA, Chari R, Erickson HK, Lambert JM. Effects of Drug-Antibody Ratio
on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of AntibodyMaytansinoid Conjugates. Bioconjug Chem. 28: 1371-1381; 2017.
17.
Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-Targeted Drug Conjugates as
an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).
Cancers (Basel). 11; 2019.
18.
Senter PDSievers EL. The discovery and development of brentuximab vedotin for
use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Nat Biotechnol. 30: 631-637; 2012.
19.
Lambert JMChari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug
conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 57: 6949-6964;
2014.
20.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler
WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H,
Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug
conjugate. Cancer Res. 68: 9280-9290; 2008.
21.
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W,
Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries
E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute
Lymphoblastic Leukemia. N Engl J Med. 375: 740-753; 2016.
22.
Appelbaum FRBernstein ID. Gemtuzumab ozogamicin for acute myeloid
leukemia. Blood. 130: 2373-2376; 2017.
23.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito
79
Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee
KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N
Engl J Med. 382: 610-621; 2020.
24.
Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, Hong EE, Niu X,
Kline J, Ison-Dugenny M, Harris S, Walker D, Krauser K, Galimi F, Wang Z,
Ghoddusi M, Mansfield K, Lee-Hoeflich ST, Holash J, Pryer N, Kluwe W,
Ettenberg SA, Sellers WR, Lees E, Kwon P, Abraham JA, Schleyer SC. Preclinical
Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against
Mutant and Wild-type c-KIT-Positive Solid Tumors. Clin Cancer Res. 24: 42974308; 2018.
25.
Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A,
Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M,
Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A,
Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D,
Foord O, Gerber HP, Sapra P, Dylla SJ. A PTK7-targeted antibody-drug conjugate
reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl
Med. 9; 2017.
26.
Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody-drug
conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin
Oncol. 14: 695-707; 2017.
27.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M,
Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE,
Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C,
Manzini S, Pellacani A, Binaschi M. MEN1309/OBT076, a First-In-Class
80
Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther.
18: 1533-1543; 2019.
28.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K,
Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ,
Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O,
Mosquera JM, Saunders L, Beltran H. Delta-like protein 3 expression and
therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 11; 2019.
29.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R,
Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S,
Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. LRRC15 Is a
Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Cancer Res. 78: 4059-4072; 2018.
30.
Sano R, Krytska K, Larmour CE, Raman P, Martinez D, Ligon GF, Lillquist JS,
Cucchi U, Orsini P, Rizzi S, Pawel BR, Alvarado D, Mossé YP. An antibody-drug
conjugate directed to the ALK receptor demonstrates efficacy in preclinical models
of neuroblastoma. Sci Transl Med. 11; 2019.
31.
Sau S, Petrovici A, Alsaab HO, Bhise K, Iyer AK. PDL-1 Antibody Drug
Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers
(Basel). 11; 2019.
32.
Wong OK, Tran TT, Ho WH, Casas MG, Au M, Bateman M, Lindquist KC, Rajpal
A, Shelton DL, Strop P, Liu SH. RN765C, a low affinity EGFR antibody drug
conjugate with potent anti-tumor activity in preclinical solid tumor models.
Oncotarget. 9: 33446-33458; 2018.
33.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K,
Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park
81
A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P,
Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis
WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ. A DLL3-targeted
antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumorinitiating cells in vivo. Sci Transl Med. 7: 302ra136; 2015.
34.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an
emerging target in small cell lung cancer. J Hematol Oncol. 12: 61; 2019.
35.
Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura
H, Harada M, Yamazaki S, Akie K, Fujita Y, Takamura K, Kojima T, Harada T,
Minami Y, Watanabe N, Oizumi S, Suzuki H, Nishimura M, Dosaka-Akita H,
Isobe H. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung
Cancer (HOT1702). Oncologist. 24: e1172-e1179; 2019.
36.
Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I,
Dosaka-Akita H, Sakakibara-Konishi J. DLL3 regulates the migration and invasion
of small cell lung cancer by modulating Snail. Cancer Sci. 110: 1599-1608; 2019.
37.
Lashari BH, Vallatharasu Y, Kolandra L, Hamid M, Uprety D. Rovalpituzumab
Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate. Drugs R D. 18: 255258; 2018.
38.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL,
Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili
S, Wolf J, Govindan R, Carbone DP. Efficacy and Safety of Rovalpituzumab
Tesirine in Third-Line and Beyond Patients with DLL3-Expressing,
Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY
Study. Clin Cancer Res. 25: 6958-6966; 2019.
39.
Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung
82
Cancer (TAHOE Study) Halted.; Available from:
https://news.abbvie.com/news/phase-3-trial-rova-t-as-second-line-therapy-foradvanced-small-cell-lung-cancer-tahoe-study-halted.htm.
40.
Sahota SVahdat LT. Sacituzumab govitecan: an antibody-drug conjugate. Expert
Opin Biol Ther. 17: 1027-1031; 2017.
41.
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a
novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an
antibody-drug conjugate (ADC). Oncotarget. 6: 22496-22512; 2015.
42.
Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT,
Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L,
Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B,
Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer
(SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC)
Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 23: 5711-5719; 2017.
43.
Yu L, Lu Y, Yao Y, Liu Y, Wang Y, Lai Q, Zhang R, Li W, Wang R, Fu Y, Tao Y, Yi
S, Gou L, Chen L, Yang J. Promiximab-duocarmycin, a new CD56 antibody-drug
conjugates, is highly efficacious in small cell lung cancer xenograft models.
Oncotarget. 9: 5197-5207; 2018.
44.
Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, Schnabel P,
Warth A, Poustka A, Sültmann H, Hoffmann H. Global gene expression analysis
reveals specific patterns of cell junctions in non-small cell lung cancer subtypes.
Lung Cancer. 63: 32-38; 2009.
45.
Bhattacharya S, Srisuma S, Demeo DL, Shapiro SD, Bueno R, Silverman EK,
Reilly JJ, Mariani TJ. Molecular biomarkers for quantitative and discrete COPD
phenotypes. Am J Respir Cell Mol Biol. 40: 359-367; 2009.
83
46.
Crouser ED, Culver DA, Knox KS, Julian MW, Shao G, Abraham S,
Liyanarachchi S, Macre JE, Wewers MD, Gavrilin MA, Ross P, Abbas A, Eng C.
Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential
pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med. 179:
929-938; 2009.
47.
Silver N, Best S, Jiang J, Thein SL. Selection of housekeeping genes for gene
expression studies in human reticulocytes using real-time PCR. BMC Mol Biol. 7:
33; 2006.
48.
Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu
H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R,
Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M,
Maheswaran S, Haber DA. Cancer therapy. Ex vivo culture of circulating breast
tumor cells for individualized testing of drug susceptibility. Science. 345: 216-220;
2014.
49.
Sunohara M, Kawakami M, Kage H, Watanabe K, Emoto N, Nagase T, Ohishi N,
Takai D. Polymerase reaction without primers throughout for the reconstruction of
full-length cDNA from products of rapid amplification of cDNA ends (RACE).
Biotechnol Lett. 33: 1301-1307; 2011.
50.
Labun K, Montague TG, Gagnon JA, Thyme SB, Valen E. CHOPCHOP v2: a web
tool for the next generation of CRISPR genome engineering. Nucleic Acids Res.
44: W272-276; 2016.
51.
Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing
CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics. 31: 11201123; 2015.
52.
Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 5:
84
22; 2017.
53.
Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into
clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 132:
777-781; 2018.
54.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA,
Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ,
Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U,
McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A,
Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J,
Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene
Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J
Med. 377: 2531-2544; 2017.
55.
Reissner C, Klose M, Fairless R, Missler M. Mutational analysis of the
neurexin/neuroligin complex reveals essential and regulatory components. Proc
Natl Acad Sci U S A. 105: 15124-15129; 2008.
56.
Harkin LF, Lindsay SJ, Xu Y, Alzu'bi A, Ferrara A, Gullon EA, James OG, Clowry
GJ. Neurexins 1-3 Each Have a Distinct Pattern of Expression in the Early
Developing Human Cerebral Cortex. Cereb Cortex. 27: 216-232; 2017.
57.
Schreiner D, Nguyen TM, Russo G, Heber S, Patrignani A, Ahrné E, Scheiffele P.
Targeted combinatorial alternative splicing generates brain region-specific
repertoires of neurexins. Neuron. 84: 386-398; 2014.
58.
Kasem E, Kurihara T, Tabuchi K. Neurexins and neuropsychiatric disorders.
Neurosci Res. 127: 53-60; 2018.
59.
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV,
Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG,
85
Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF. Molecular subtypes of
small cell lung cancer: a synthesis of human and mouse model data. Nat Rev
Cancer. 19: 289-297; 2019.
60.
Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard
L, Minna JD, Gazdar AF, Cobb MH, Johnson JE. ASCL1 and NEUROD1 Reveal
Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct
Genetic Programs. Cell Rep. 16: 1259-1272; 2016.
61.
Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK,
Pacak K, Oliver TG, Minna JD, Gazdar AF. Small cell lung cancer tumors and
preclinical models display heterogeneity of neuroendocrine phenotypes. Transl
Lung Cancer Res. 7: 32-49; 2018.
62.
Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ,
Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P,
Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy
of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug
Conjugate, Sacituzumab Govitecan. J Clin Oncol. 35: 2790-2797; 2017.
63.
Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S,
Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. Association of tumor
TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget.
8: 28725-28735; 2017.
86
...
論文の公開元へ
